- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03779997
Trial of Adherence App for Buprenorphine Treatment (TAAB) Study
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders With Buprenorphine
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The objective of this study is to compare an innovative mobile health (mHealth) platform to support participants being treated for opioid use disorder (OUD) with buprenorphine to treatment-as-usual (TAU). The application will provide video-based directly observed therapy (VDOT) which may result in better health outcomes for participants and less public health risk for diversion. This study is a randomized controlled trial with two arms: TAU and mHealth intervention. Randomization to the two study arms will be completed using computer randomization procedures. Participants in the intervention group will learn how to use the mHealth application on their personal smartphones or tablets. If a participant does not have access to a personal device or prefers to not use a personal device then a study-provided smartphone will be offered for the duration of the study. Intervention participants are asked to record one daily video of themselves taking buprenorphine. Buprenorphine clinical staff (i.e., physicians, nurses and medical assistants) of patients enrolled in the intervention group will be trained and have the opportunity to review the videos. Adherence for the intervention group will be measured through participation in VDOT, namely the percentage of daily medication doses that are observed through submitted videos. The TAU group will not be given access to the intervention and therefore will not have the opportunity to be exposed to the intervention.
All participants will follow the same visit schedule. Interviews will occur at baseline (Week 0) and the final visit (Week 12) to assess current and prior substance use, treatment history, medication adherence, drug diversion, general physical and mental health and treatment satisfaction. A point of care urine drug test will also be administered which will assess for opiates and other substances. In between the baseline and final visits, participants will meet with research staff weekly to conduct a urine drug test and assess self-reported adherence to buprenorphine. Research staff will review the electronic medical record at baseline and week 12 to assess engagement in treatment. Additionally, at 24 weeks post-enrollment the research staff will complete a review of the electronic medical record and record engagement in clinic treatment, changes in buprenorphine treatment during the study period and the results of any clinical urine drug testing.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02118
- Boston University
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- University of Washington
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- ≥18 years old
- Receiving buprenorphine treatment at an office-based buprenorphine program for ≤4 weeks
- Willing to be randomized to either VDOT or TAU
Exclusion Criteria:
- Unable or unwilling to use smart phone
- Cognitive impairment resulting in inability to provide informed consent
- Researcher's discretion that participant will not be appropriate for participation in the study (e.g. participant is planning on moving away, is knowledgeable of future incarceration during the study, or has behavioral issues that may pose safety concerns for clinic and research staff)
- Inability to read and understand English as needed for following app instructions
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Video-based DOT Application
|
Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine.
Clinical staff (i.e.
physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
|
Geen tussenkomst: Behandeling zoals gebruikelijk (TAU)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage Opioid Negative Urine Tests
Tijdsspanne: Baseline to 12 weeks post-randomization
|
Percentage of weekly study urine drug tests that are negative for opioids, missing assumed to be positive.
|
Baseline to 12 weeks post-randomization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants Engaged in Treatment at Week 12
Tijdsspanne: Week 12 post-randomization
|
The percentage of participants with an active script for buprenorphine at week 12 (engaged in treatment), measured by electronic health record (EHR) review.
|
Week 12 post-randomization
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants Engaged in Treatment at Week 24
Tijdsspanne: Week 24 post-randomization
|
The percentage of participants engaged in treatment at 24 weeks post-randomization, measured by EHR review.
|
Week 24 post-randomization
|
Consecutive Weeks Opioid Negative Urine Tests
Tijdsspanne: Baseline to 12 weeks post-randomization
|
The number of consecutive weeks with urine drug test negative for opioids.
|
Baseline to 12 weeks post-randomization
|
Number of Participants With Self-report of Opioid Use
Tijdsspanne: Week 12 post-randomization
|
Self-reported use of illicit opioids in past 30 days at week 12.
|
Week 12 post-randomization
|
Buprenorphine Adherence Self-Report
Tijdsspanne: Baseline to 12 weeks post-randomization
|
Mean number of days adherent to buprenorphine by self-report over the 12-week study period, using a 7-day timeline-follow-back (TLFB) survey procedure each week.
Days with missing data were excluded from analysis.
|
Baseline to 12 weeks post-randomization
|
Treatment Discharge
Tijdsspanne: Baseline to 24 weeks post-randomization
|
Time to discharge from treatment, measured by EHR review.
|
Baseline to 24 weeks post-randomization
|
Buprenorphine Non-use: One or More UDT Negative for Buprenorphine
Tijdsspanne: Baseline to 12 weeks post-randomization
|
Having one or more study urine drug tests negative for buprenorphine
|
Baseline to 12 weeks post-randomization
|
UDT Positive for Stimulants at Week 12
Tijdsspanne: Week 12 post-randomization
|
Number of participants having a study urine drug test positive for stimulants (cocaine, amphetamines or methamphetamines).
|
Week 12 post-randomization
|
Treatment Satisfaction
Tijdsspanne: Week 12 post-randomization
|
Likert scale survey question of participant's satisfaction with clinic's treatment of opioid use disorder (OUD); on a scale of 1-5, with 1 being very dissatisfied and 5 being very satisfied.
|
Week 12 post-randomization
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Judith I. Tsui, MD, MPH, University of Washington
Publicaties en nuttige links
Algemene publicaties
- Schramm ZA, Leroux BG, Radick AC, Ventura AS, Klein JW, Samet JH, Saxon AJ, Kim TW, Tsui JI. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial. Addict Sci Clin Pract. 2020 Jul 31;15(1):30. doi: 10.1186/s13722-020-00203-9.
- Tsui JI, Leroux BG, Radick AC, Schramm ZA, Blalock K, Labelle C, Heerema M, Klein JW, Merrill JO, Saxon AJ, Samet JH, Kim TW. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial. Drug Alcohol Depend. 2021 Oct 1;227:108917. doi: 10.1016/j.drugalcdep.2021.108917. Epub 2021 Jul 28.
- Radick AC, James J, Leroux BG, Kim TW, Saxon AJ, Samet JH, Tsui JI. Use of Video Directly Observed Therapy and Characteristics Associated With Use Among Patients Treated With Buprenorphine in an Office-based Setting. J Addict Med. 2022 Oct 24. doi: 10.1097/ADM.0000000000001103. Online ahead of print.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- STUDY00005069
- 4R44DA044053-02 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Aan opioïden gerelateerde aandoeningen
-
University of HoustonOnbekend
-
New York City Health and Hospitals CorporationBeëindigdGlaucoom | Ziekte van het netvlies | Visuele Pathway DisorderVerenigde Staten
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCAanmelden op uitnodigingMacula ziekte | Visuele Pathway Disorder | Ziekte van de oogzenuwVerenigde Staten
-
Fondazione G.B. Bietti, IRCCSVoltooidGlaucoom | Optische neuropathie, ischemische | Optische zenuw | Visuele Pathway Disorder | Neurale geleidingItalië
-
University of MiamiNational Eye Institute (NEI)VoltooidGlaucoom | Maculaire degeneratie | Retinale degeneratie | Optische neuropathie | DrDeramus verdachte | Visuele Pathway DisorderVerenigde Staten
-
Isfahan University of Medical SciencesVoltooidZiekte van Tanger | Body Mass Index Quantitative Trait Locus 5 DisorderIran, Islamitische Republiek
-
Weill Medical College of Cornell UniversityUniversity of California, Los Angeles; University of Wisconsin, MilwaukeeVoltooidTourette syndroom | De stoornis van Gilles de la Tourette | Gilles de la Tourette | Gilles de la Tourette-syndroom | Ziekte van Gilles de la Tourette | Tourette-ziekte | Tic Disorder, Gecombineerde Vocale en Multiple Motor | Meerdere motorische en vocale ticstoornis, gecombineerd | Ziekte van Gilles... en andere voorwaarden
Klinische onderzoeken op Video-based DOT Application
-
University of GeorgiaMakerere UniversityVoltooid
-
Centers for Disease Control and PreventionColumbia University; New York City Department of Health and Mental HygieneVoltooidTuberculose | Aanhankelijkheid, medicatie | Medicijnresistente tuberculose | Aanhankelijkheid, patiëntVerenigde Staten
-
Johns Hopkins UniversityCenters for Disease Control and PreventionVoltooidOpioïdengebruikstoornisVerenigde Staten
-
University of California, San DiegoVoltooidTuberculose | Latente tuberculose-infectieVerenigde Staten
-
University of California, DavisCenters for Disease Control and PreventionVoltooidSuïcidale gedachten | Zelfmoord, poging tot | Suïcidale intentieVerenigde Staten